- Current report filing (8-K)
May 05 2010 - 4:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
May 5,
2010
ALLOS THERAPEUTICS, INC.
(Exact name of
registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No.)
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Section 2
Financial Information
Item 2.02
Results of Operations
and Financial Condition.
On May 5, 2010, Allos Therapeutics, Inc., a
Delaware corporation, issued a press release reporting financial results for
the first quarter of fiscal year 2010. The press release is attached
hereto as Exhibit 99.1, which is furnished under Item 2.02 of this report
and shall not be deemed to be filed for purposes of Section 18 of the
Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
regardless of any general incorporation language in such filing.
Section 9
Financial Statements and
Exhibits
Item 9.01
Financial Statements and
Exhibits.
(d)
Exhibits.
99.1
Press Release, dated May 5, 2010,
entitled Allos Therapeutics Reports
First Quarter 2010 Financial Results.
2
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
Dated:
May 5, 2010
|
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press Release, dated
May 5, 2010, entitled Allos
Therapeutics Reports First Quarter 2010 Financial Results.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From May 2024 to Jun 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2023 to Jun 2024